529 related articles for article (PubMed ID: 28994264)
21. Immunotherapy for melanoma.
Cuevas LM; Daud AI
Semin Cutan Med Surg; 2018 Jun; 37(2):127-131. PubMed ID: 30040090
[TBL] [Abstract][Full Text] [Related]
22. New drug targets in metastatic melanoma.
Homet B; Ribas A
J Pathol; 2014 Jan; 232(2):134-41. PubMed ID: 24027077
[TBL] [Abstract][Full Text] [Related]
23. A new era in the treatment of melanoma: from biology to clinical practice.
Márquez-Rodas I; Martín Algarra S; Avilés Izquierdo JA; Custodio Cabello S; Martín M
Clin Transl Oncol; 2011 Nov; 13(11):787-92. PubMed ID: 22082642
[TBL] [Abstract][Full Text] [Related]
24. [Genetic diversity and immunological characteristics of malignant melanoma: the therapeutic spectrum].
Doma V; Gulya E
Orv Hetil; 2015 Apr; 156(15):583-91. PubMed ID: 25845317
[TBL] [Abstract][Full Text] [Related]
25. Novel Targets in Melanoma: Intralesional and Combination Therapy to Manipulate the Immune Response.
Gingrich AA; Kirane AR
Surg Oncol Clin N Am; 2020 Jul; 29(3):467-483. PubMed ID: 32482321
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapy for advanced melanoma: fulfilling the promise.
Gogas H; Polyzos A; Kirkwood J
Cancer Treat Rev; 2013 Dec; 39(8):879-85. PubMed ID: 23725878
[TBL] [Abstract][Full Text] [Related]
27. Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors.
Gentzler R; Hall R; Kunk PR; Gaughan E; Dillon P; Slingluff CL; Rahma OE
Immunotherapy; 2016 May; 8(5):583-600. PubMed ID: 27140411
[TBL] [Abstract][Full Text] [Related]
28. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017.
Ugurel S; Röhmel J; Ascierto PA; Flaherty KT; Grob JJ; Hauschild A; Larkin J; Long GV; Lorigan P; McArthur GA; Ribas A; Robert C; Schadendorf D; Garbe C
Eur J Cancer; 2017 Sep; 83():247-257. PubMed ID: 28756137
[TBL] [Abstract][Full Text] [Related]
29. Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment.
Vella LJ; Andrews MC; Behren A; Cebon J; Woods K
Expert Rev Clin Immunol; 2014 Aug; 10(8):1107-23. PubMed ID: 24939732
[TBL] [Abstract][Full Text] [Related]
30. State of melanoma: an historic overview of a field in transition.
Gorantla VC; Kirkwood JM
Hematol Oncol Clin North Am; 2014 Jun; 28(3):415-35. PubMed ID: 24880939
[TBL] [Abstract][Full Text] [Related]
31. [Not Available].
Mateus C; Libenciuc C; Robert C
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
[TBL] [Abstract][Full Text] [Related]
32. [New melanoma immunotherapies: mechanisms of action, efficiency and management of toxicities].
Moura B; Homicsko K; Berthod G; Cerottini JP; Guggisberg D; Gaide O; Maillard MH; Michielin O
Rev Med Suisse; 2015 May; 11(475):1108, 1110-4. PubMed ID: 26152085
[TBL] [Abstract][Full Text] [Related]
33. Next-Generation Sequencing to Guide Treatment of Advanced Melanoma.
Griewank KG; Schilling B
Am J Clin Dermatol; 2017 Jun; 18(3):303-310. PubMed ID: 28229402
[TBL] [Abstract][Full Text] [Related]
34. The biology and therapeutic management of melanoma brain metastases.
Abate-Daga D; Ramello MC; Smalley I; Forsyth PA; Smalley KSM
Biochem Pharmacol; 2018 Jul; 153():35-45. PubMed ID: 29278675
[TBL] [Abstract][Full Text] [Related]
35. Harnessing the immune system for the treatment of melanoma: current status and future prospects.
Guennoun A; Sidahmed H; Maccalli C; Seliger B; Marincola FM; Bedognetti D
Expert Rev Clin Immunol; 2016 Aug; 12(8):879-93. PubMed ID: 27070898
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy of Melanoma.
Bender C; Hassel JC; Enk A
Oncol Res Treat; 2016; 39(6):369-76. PubMed ID: 27259558
[TBL] [Abstract][Full Text] [Related]
37. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
[TBL] [Abstract][Full Text] [Related]
38. [Novel treatment options must prove their effectiveness: targeted treatment and immunotherapy for locally advanced melanoma].
van Thienen JV
Ned Tijdschr Geneeskd; 2018 Jun; 162():. PubMed ID: 30040280
[TBL] [Abstract][Full Text] [Related]
39. A role of immunotherapy in metastatic malignant melanoma.
Allen T; Gundrajakuppam L
Cent Nerv Syst Agents Med Chem; 2012 Sep; 12(3):182-8. PubMed ID: 22697295
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy for advanced melanoma: Current knowledge and future directions.
Nakamura K; Okuyama R
J Dermatol Sci; 2016 Aug; 83(2):87-94. PubMed ID: 27302423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
